Last edition
News about "KEYTRUDA "
Zydus Partners with Bioeq for US Commercialisation of Lucentis Biosimilar
Zydus has entered into a partnership with Bioeq to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market. Under the agreement, Bioeq will handle development, manufacturing, regulatory approval and product supply, while Zydus will oversee US commercialisation.
Keytruda | 24/12/2025 | By News Bureau
KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC
KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.
KEYTRUDA | 18/12/2025 | By News Bureau
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Keytruda | 15/11/2025 | By Dineshwori | 196
EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer
KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.
KEYTRUDA | 30/10/2025 | By Dineshwori | 118
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
KEYTRUDA | 11/10/2025 | By Dineshwori | 700
Dr. Reddy's Injects INR 565 Crore into Russian Arm
Dr Reddy’s Laboratories Ltd has invested INR 565.4 crore in its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19 percent equity stake in the step-down wholly-owned subsidiary.
Keytruda | 29/07/2025 | By Dineshwori | 404
ABL Bio Signs Clinical Alliance with MSD to Evaluate ABL103 with KEYTRUDA
Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will supply KEYTRUDA.
KEYTRUDA | 07/10/2024 | By Aishwarya | 528
Dragonfly Therapeutics Partners with Merck to Evaluate DF9001
Dragonfly Therapeutics, Inc. has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada), to evaluate DF9001, Dragonfly's EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors expressing EGFR.
KEYTRUDA | 22/05/2024 | By Aishwarya | 495
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy